- Home
- NXL vs HKPD Comparison
NXL vs HKPD Comparison
Compare NXL & HKPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXL
- HKPD
- Stock Information
- Founded
- NXL 2010
- HKPD 2016
- Country
- NXL United States
- HKPD Hong Kong
- Employees
- NXL N/A
- HKPD N/A
- Industry
- NXL Medical Specialities
- HKPD Other Pharmaceuticals
- Sector
- NXL Health Care
- HKPD Health Care
- Exchange
- NXL Nasdaq
- HKPD Nasdaq
- Market Cap
- NXL 21.0M
- HKPD 20.9M
- IPO Year
- NXL 2022
- HKPD 2025
- Fundamental
- Price
- NXL $1.12
- HKPD $1.37
- Analyst Decision
- NXL Strong Buy
- HKPD
- Analyst Count
- NXL 1
- HKPD 0
- Target Price
- NXL $5.00
- HKPD N/A
- AVG Volume (30 Days)
- NXL 116.3K
- HKPD 186.7K
- Earning Date
- NXL 08-07-2025
- HKPD 01-01-0001
- Dividend Yield
- NXL N/A
- HKPD N/A
- EPS Growth
- NXL N/A
- HKPD N/A
- EPS
- NXL N/A
- HKPD 0.21
- Revenue
- NXL $131,065.00
- HKPD $20,770,344.00
- Revenue This Year
- NXL $79.59
- HKPD N/A
- Revenue Next Year
- NXL $334.65
- HKPD N/A
- P/E Ratio
- NXL N/A
- HKPD $6.51
- Revenue Growth
- NXL N/A
- HKPD 32.91
- 52 Week Low
- NXL $0.59
- HKPD $0.81
- 52 Week High
- NXL $4.49
- HKPD $3.79
- Technical
- Relative Strength Index (RSI)
- NXL 54.25
- HKPD N/A
- Support Level
- NXL $0.97
- HKPD N/A
- Resistance Level
- NXL $1.08
- HKPD N/A
- Average True Range (ATR)
- NXL 0.08
- HKPD 0.00
- MACD
- NXL 0.03
- HKPD 0.00
- Stochastic Oscillator
- NXL 70.00
- HKPD 0.00
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
About HKPD Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and (ii) OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.